Categories: All postsAnalysts

Is 5N Plus stock a buy? (November, 2024)

Following the company’s third quarter results, Desjardins Securities analyst Frederic Tremblay has raised his price target on 5N Plus (5N Plus Stock Quote, Chart, News, Analysts, Financials TSX:VNP).

On November 4, VNP reported its Q3, 2024 results. The company posted Adjusted EBITDA of $15.6-million on revenue of $78.8-million, a topline that was up 25% year-over-year.

“Our strong results in the third quarter of 2024 reflect sustained growth momentum in our Specialty Semiconductors business, coupled with a stellar performance by our Performance Materials segment,” CEO Gervais Jacques said. “Our teams are also executing seamlessly on the operational front with our specialty semiconductor capacity initiatives, enabling us to meet near term contracted demand and to efficiently expand capacity in future. Given our strong results year to date, we now expect to be able to surpass our previously disclosed guidance range and to slightly exceed $50 million in Adjusted EBITDA for the full fiscal year.”

As reported by the Globe and Mail, Tremblay November 5 maintained his “Buy” rating on VNP and raised his price target on the stock from $8.50 to $8.75.

The analyst says it’s a good time to buy the stock.

“We view the current share price as a good entry point,” he wrote. “Quarterly fluctuations aside, we are pleased with VNP being on track to exceed its previously disclosed full-year guidance in 2024. Doing so would reinforce our view that the unchanged 2025 guidance is conservative. Operationally, recent and upcoming capacity increases support VNP’s strong positioning in its core growth markets.”

Tagged with: vnp
Staff

Recent Posts

Hut 8 stock: Buy, Sell or Hold?

Roth Capital Partners analyst Bryan Baratian maintained his “Buy” rating and US$108.00 target on Hut 8 (Hut 8 Stock Quote,… [Read More]

6 hours ago

This investor explains why he loves Topicus stock

Baskin Wealth Management president and chief investment officer Barry Schwartz named Topicus.com (Topicus.com Stock Quote, Chart, News, Analysts, Financials TSX:TOI)… [Read More]

6 hours ago

RNA stock: time to buy?

On Oct. 29 Roth Capital Partners analyst Boobalan Pachaiyappan maintained his “Buy” rating and US$15.00 target on Atrium Therapeutics (Atrium… [Read More]

6 hours ago

TD raises price target on Coveo Solutions

TD Cowen analyst David Kwan raised his target on Coveo Solutions (Coveo Solutions Stock Quote, Chart, News, Analysts, Financials TSX:CVO)… [Read More]

10 hours ago

Electrovaya has an upside of 143%, this analyst says

Roth Capital Partners analyst Craig Irwin maintained his “Buy” rating and US$14.00 target on Electrovaya (Electrovaya Stock Quote, Chart, News,… [Read More]

12 hours ago

Analyst raises his price target on Kinaxis to $225.00

Stifel analyst Suthan Sukumar raised his target on Kinaxis (Kinaxis Stock Quote, Chart, News, Analysts, Financials:TSX:KXS) to $225.00 from $200.00,… [Read More]

12 hours ago